<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1616">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360122</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU P20a/ 2020</org_study_id>
    <nct_id>NCT04360122</nct_id>
  </id_info>
  <brief_title>Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19</brief_title>
  <official_title>Impact of Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized open labeled clinical trial will include one hundred healthy healthcare&#xD;
      workers who will be randomly assigned into four groups of twenty-five each to receive either&#xD;
      levamisole, Isoprinosine, combined levamisole and isoprinosine or no-intervention for two&#xD;
      months to detect the impact of Levamisole and Isoprinosine as immune-prophylaxis on the&#xD;
      incidence of COVID-19 infection. Participants will be followed-up for three months clinically&#xD;
      and laboratory. Blood samples will be collected prior to randomization and during follow up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One hundred healthy health workers will be randomly assigned to receive either Levamisole,&#xD;
      Isoprinosine, Levamisole and Isoprinosine or no-intervention for two months. Written informed&#xD;
      consent will be obtained from all participants.&#xD;
&#xD;
      During the study:&#xD;
&#xD;
        1. Participants will be assessed by detailed questionnaire, clinically and laboratory&#xD;
           investigations for COVID 19 Detailed questionnaire for: job description, site of&#xD;
           isolation hospital, duration of contact, time of exposure, methods of protection&#xD;
           Clinically for any symptoms suggestive of COVID19: fever, plus at least one sign or&#xD;
           symptom of respiratory disease including cough, shortness of breath, respiratory&#xD;
           distress/failure, runny/blocked nose, plus Laboratory: Sampling of the following will be&#xD;
           withdrawn from all participants at beginning and end of the study: COVID 19 IgM (for&#xD;
           recent infection) or IgG or (old infection)&#xD;
&#xD;
        2. Assessment of the modulatory effect of the drugs will be done by one or more of the&#xD;
           following parameters: (at beginning of the study, 2 weeks, 1 month, 2-month, 3 month)&#xD;
&#xD;
             -  Neutrophil function test&#xD;
&#xD;
             -  Natural killer cell count and activity.&#xD;
&#xD;
             -  T cell count and B cell subsets by flowcytometry and activity markers&#xD;
&#xD;
             -  Quantitative immunoglobulines Levels (IgG, IgM, IgA, IgE)&#xD;
&#xD;
        3. Assessment of the drug safety at beginning of the study and every two weeks except for&#xD;
           complete blood count every week:&#xD;
&#xD;
             -  Urine analysis&#xD;
&#xD;
             -  Complete blood count with differential to determine total white blood cell count,&#xD;
                absolute neutrophilic count (to exclude agranulocytosis) and absolute lymphocytic&#xD;
                count (for COVID19).&#xD;
&#xD;
             -  Serum uric acid&#xD;
&#xD;
             -  Renal functions tests&#xD;
&#xD;
             -  Liver function tests&#xD;
&#xD;
      Randomization method:&#xD;
&#xD;
      A block-randomization scheme will be generated by computer software. Computer-generated&#xD;
      random numbers will randomize the participants into four intervention groups of 25 each. The&#xD;
      patients were randomly assigned to receive either Isoprinosine (1 g 3 times per day daily) or&#xD;
      Levamisole (150 mg/day for two days per week), both or no-intervention for two months.&#xD;
&#xD;
      End point of the study:&#xD;
&#xD;
        -  Refusal of patient to complete the study.&#xD;
&#xD;
        -  Non-compliance on treatment&#xD;
&#xD;
        -  Agranulocytosis or thrombocytopenia.&#xD;
&#xD;
        -  Hyperuricemia.&#xD;
&#xD;
        -  COVID19 infection&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 20, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase III, randomized, open labelled, clinical trial on one hundred adult healthy healthcare workers</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease the incidence of COVID-19 infection or its severity</measure>
    <time_frame>6 months</time_frame>
    <description>Detect if Levamisole and Isoprinosine can decrease the incidence of COVID-19 infection</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronavirus Disease (COVID-19)</condition>
  <arm_group>
    <arm_group_label>Levamisole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Levamisole 150 mg/day for two days per week for two months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isoprinosine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Isoprinosine 1 g 3 times per day daily for two months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levamisole and Isoprinosine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Levamisole 150 mg/day for two days per week and Oral Isoprinosine 1 g 3 times per day daily for two months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-interventional group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No-intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levamisole</intervention_name>
    <description>Levamisole (150 mg/day for two days per week for 2 months</description>
    <arm_group_label>Levamisole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoprinosine</intervention_name>
    <description>Isoprinosine (1 g 3 times per day daily) for two months</description>
    <arm_group_label>Isoprinosine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levamisole and Isoprinosine</intervention_name>
    <description>Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months</description>
    <arm_group_label>Levamisole and Isoprinosine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult &gt; 18 years old&#xD;
&#xD;
          -  Both Gender (male and female)&#xD;
&#xD;
          -  Healthy health care workers employed by one of the hospitals involved in the study&#xD;
&#xD;
          -  Negative serology at day 0 for COVID19 infection.&#xD;
&#xD;
          -  Evidence of a personally signed and dated informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participations in other investigational clinical trials for the treatment or&#xD;
             prevention of SARS-COV-2 infection&#xD;
&#xD;
          -  Previous or recent COVID 19 infection (previously had a SARS-CoV-2 positive test&#xD;
             result or confirmed case of SARS-CoV-2 infection or positive serology at day 0)&#xD;
&#xD;
          -  Any medical illness&#xD;
&#xD;
          -  Has a congenital immunodeficiency, including specific deficiencies of the&#xD;
             interferon-gamma pathway&#xD;
&#xD;
          -  Participants receiving steroids, cytotoxic immunosuppressive agents, radiotherapy.&#xD;
&#xD;
          -  Participants who have received any other immunotherapy.&#xD;
&#xD;
          -  Participants with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction&#xD;
             and severe gastric ulcer.&#xD;
&#xD;
          -  Participants receiving allopurinol, indomethacin, colchicine or diuretics.&#xD;
&#xD;
          -  Participants with hematological problems.&#xD;
&#xD;
          -  Known hypersensitivity reactions or Wheat Allergy&#xD;
&#xD;
          -  Pregnant and lactating females.&#xD;
&#xD;
          -  Refusal to sign the informed consent form&#xD;
&#xD;
          -  Refusal of participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mariam Amin, MD</last_name>
    <phone>01224532769</phone>
    <phone_ext>002</phone_ext>
    <email>mariamaged@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center</name>
      <address>
        <city>Cairo</city>
        <state>Non-US</state>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Fatma Soliman E Ebeid</last_name>
      <phone>01095569596</phone>
      <email>dr.fatma_ebeid@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>May 3, 2020</last_update_submitted>
  <last_update_submitted_qc>May 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Maged Mohammed Refaat</investigator_full_name>
    <investigator_title>Professor of Allergy and Clinical Immunology.Faculty of Medicine Ain Shams University</investigator_title>
  </responsible_party>
  <keyword>Egypt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levamisole</mesh_term>
    <mesh_term>Inosine Pranobex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

